CERS6

Across TCGA pan-cancer cohorts, CERS6 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CERS6 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CERS6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CERS6 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

HNSC, GBM, and LUAD are the cancer types where CERS6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.698	1.000	.031	8	view →
GBM	OS	Quartile	All	0.648	0.360	.026	6	view →
LUAD	OS	Tertile	All	1.000	0.906	.032	4	view →
CCRCC	OS	Median	II,III,IV	0.959	0.621	.023	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CERS6–HNSC (DFS)

Open the HNSC breakdown →